Chad Hellmann
Chief Financial Officer
Mr. Hellmann joined TILT as Strategic Advisor for Capital Strategy in 2025 and is transitioning into CFO role at TiltBio Inc. Mr. Hellmann serves also as Managing Partner at Remedium Capital Partners, an oncology-focused private and public market investment firm. During his tenure at his previous investment firm, Arcus Ventures, Mr. Hellmann spent a year as the interim CFO of NLS Pharmaceutics, AG, a Swiss-based, Nasdaq-listed, late-stage clinical development CNS company where he successfully removed two Nasdaq listing deficiency issues while transitioning the investor base to fundamental holders.
Mr. Hellmann’s 25-year investment career on the buy-side has spanned the spectrum of private equity, venture capital, private debt, and public capital markets with over 15 of those years focused on the oncology sector. From 2004 through 2011, Mr. Hellmann served as CFO of an SFO and a partner of a private equity spin-off fund focused on technology, biotech and cleantech companies in the private and public markets. After obtaining his MBA, Mr. Hellmann spent two years at UBS Warburg in investment banking.
